{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-023963","form_type":"8-K","ticker":null,"cik":"0001169987","company_name":"HTG MOLECULAR DIAGNOSTICS, INC","filed_at":"2023-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.130446+00:00","generated_at":"2026-06-14T15:41:51.860724+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nasdaq notifies HTG Molecular of delisting risk for equity below $2.5M","bullets":["Nasdaq notice on May 18, 2023: stockholders' equity fell below $2.5M as of March 31, 2023.","Company must submit a compliance plan by July 3, 2023 under Nasdaq Rule 5550(b).","If plan is accepted, Nasdaq may grant up to 180-day extension for evidence of compliance.","No assurance of regaining compliance; delisting remains a possibility."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-023963","json":"https://secwatch.observer/filing/0000950170-23-023963.json","markdown":"https://secwatch.observer/filing/0000950170-23-023963.md","text":"https://secwatch.observer/filing/0000950170-23-023963.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1169987/000095017023023963/0000950170-23-023963-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1169987/000095017023023963/htgm-20230518.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T15:41:51.860724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3304d331fdad0456f9300f9f9cc706b07802046a","claim":"HTG MOLECULAR DIAGNOSTICS, INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)).","evidence_excerpt":"May 18, 2023, HTG Molecular Diagnostics, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that, as a result of the Company’s stockholders’ equity falling below $2.5 million, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, the Company does not satisfy one of The Nasdaq Capital Market continued listing requirement set forth in Nasdaq Stock Market Rule 5550(b) (the “Rule”). Pursuant to the Notice and Nasdaq rules, the Company has 45 calendar days, or until July 3, 2023, to submit a plan to regain compl","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1169987/000095017023023963/0000950170-23-023963-index.htm","confidence":0.98,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}